Introduction
============

Colorectal cancer (CRC) is one of the most common cancers worldwide and has been estimated as the third most frequently diagnosed cancer in both men and women in the USA.[@b1-ott-8-211] The overall survival rate of patients with CRC is highly dependent upon the stage of the disease at the time of diagnosis. The estimated 5-year survival rate ranges from 85% to 90% for patients with stage I CRC to \<5% for patients with stage IV CRC.[@b2-ott-8-211] Although the annual death rate has declined by 3% for CRC in the past 10 years, nearly 142,820 US residents were diagnosed with CRC in 2013.[@b1-ott-8-211] Several risk factors, including obesity, red meat consumption, and cigarette smoking, have been found to be associated with a higher risk of developing CRC.[@b3-ott-8-211] Additionally, genetic and epigenetic alterations play crucial roles in the pathogenesis of CRC.[@b4-ott-8-211]--[@b6-ott-8-211]

It has been demonstrated that DNA methylation at CpG islands and its associated silencing of gene expression are important causes of the tumorigenesis of CRC.[@b2-ott-8-211],[@b7-ott-8-211] These epigenetic changes substantially contribute to cellular transformation, particularly if these changes affect the genes that are involved in maintaining genomic stability. Due to the high sensitivity, specificity, and convenience of methylation detection methods, mounting evidence has indicated that DNA methylation patterns may be promising biomarkers when predicting one's risk of developing CRC, as well as for determining patient outcomes.[@b8-ott-8-211] Among the hypermethylated genes that have been identified in CRC, the adenomatous polyposis coli (*APC*) gene is a well-characterized tumor suppressor gene. The *APC* gene, which is located at chromosomal band 5q21--q22, comprises 15 exons. Its tumor-suppressing activity is mainly attributed to regulation of the intracellular level of β-catenin within the Wingless signal transduction pathway.[@b9-ott-8-211] It has been demonstrated that *APC* mutations are one of the earliest events that occur in the initiation and progression of CRC.[@b10-ott-8-211],[@b11-ott-8-211] In addition, previous oncogenetic tree analysis has shown that *APC* alterations are the first to occur in an independent branch, and these predispose an individual to other gene alterations that occur in the pathways associated with colon tumorigenesis.[@b12-ott-8-211] To date, several studies have evaluated the association between *APC* promoter methylation and the risk of developing CRC (or the clinical characteristics of CRC) in patients. However, the results of these studies remain a matter of debate. Compared with in silico analyses, which are also dependent upon computer-based statistical analysis methods and have been used in the prediction of disease-associated gene mutation,[@b13-ott-8-211] the design of new drugs,[@b14-ott-8-211] and the analysis of molecular and structural mechanisms,[@b15-ott-8-211],[@b16-ott-8-211] meta-analyses have been widely applied to identify potential sources of disagreement between study results. Therefore, we conducted a meta-analysis to comprehensively evaluate the association of *APC* promoter methylation with CRC risk and the clinical characteristics observed in CRC patients in order to provide evidence for the future application of *APC* in the prevention and treatment of CRC.

Methods
=======

Search strategy
---------------

We conducted a literature search using the PubMed (search updated to October 2014; <http://www.ncbi.nlm.nih.gov/pubmed/>), Embase, and MEDLINE (search updated to October 2014; <http://www.embase.com/>) databases using the following search terms located in either the title or abstract: ("adenomatous polyposis coli" or *APC*) and (methylation, hypermethylation, methylated, or hypomethylation) and ("colorectal neoplasms", "colorectal cancer", "colon cancer", "rectal cancer", "colorectal carcinoma", "rectal carcinoma", "colon carcinoma", "colon neoplasms", or "rectal neoplasms"). The search was limited to human studies. Additionally, we hand-searched the references of the review articles and, as needed, contacted the first author of a given paper to obtain any missing data.

Study selection
---------------

Studies were selected for the current meta-analysis according to the following criteria: they determined *APC* promoter methylation in specimens of colorectal tissue, blood, plasma, serum, buffy coat, or urine; and they provided sufficient information to evaluate odds ratios (ORs) and 95% confidence intervals (CIs). In addition, when the same author or group reported results that were obtained from the same patient population in more than one article, only the most recent or most informative report was included. Our exclusion criteria were: review articles or conference reports; a lack of information about the degree of *APC* promoter methylation in patient cases and controls; and when screening for methylation of the *APC* promoter was conducted in cell lines.

Quality assessment
------------------

The assessment of study quality was conducted independently by two reviewers using the Newcastle-Ottawa Scale (NOS).[@b17-ott-8-211] The NOS evaluation system consists of three parameters (selection, comparability, and outcome) and assigns a maximum of four points for selection, two points for comparability, and three points for outcome. A NOS score \>6 indicates a higher quality study, whereas a score ≤6 indicates a lower quality study. Any discrepancies between the two reviewers were settled by a third reviewer.

Data extraction
---------------

The data were extracted independently by two authors, and discrepancies were resolved by consensus including a third author. The data were collected using a pilot-tested data extraction form that included the following items: the first author's name; the year of publication; the number of participants that exhibited *APC* promoter methylation both among specific cases and controls; the screening methods used; and the demographic and clinical characteristics of the patients. All procedures conformed to the established guidelines for the meta-analysis of observational studies in epidemiology.[@b18-ott-8-211]

Statistical analysis
--------------------

The meta-analysis was performed using Stata software (version 11; StataCorp LP, College Station, TX, USA). The association between *APC* promoter methylation and the risk of developing CRC or its clinical characteristics (such as Dukes' stages, TNM stages, metastasis, differentiation grade, as well as differences based on patient sex and age) was measured either by weighted OR by taking into account the 95% CI. We tested for heterogeneity among the studies using the chi-square-based *Q*-test and the *I*^2^ statistic of inconsistency. Significant heterogeneity was defined as a chi-square test *P*-value \<0.10 or as an *I*^2^ statistic \>50%.[@b19-ott-8-211] We used a random-effects model when significant heterogeneity was observed among the studies; otherwise, we used a fixed-effects model. For a two-tailed significance level of 5%, the probability of rejecting the null hypothesis when it was false was termed the power, which was defined as 1 -- β.

Funnel plots and Egger's test were used to assess publication bias. Additionally, prespecified subgroup analyses, which included the patients' ethnicities, as well as the test samples, testing methods, and sample sizes, were conducted to evaluate potential sources of heterogeneity within the studies investigating the association between *APC* promoter methylation and the risk of CRC or CRC metastasis. Moreover, sensitivity analyses were performed to examine the influence of each study on the pooled OR by serially omitting each individual study and pooling the remaining studies.

Results
=======

Results of the literature search
--------------------------------

[Figure 1](#f1-ott-8-211){ref-type="fig"} illustrates the detailed process used for study selection. In summary, a total of 333 articles were initially identified; of these, 268 articles were excluded, either based on duplicate results or because they were deemed to be irrelevant to this meta-analysis after careful review of the titles and abstracts. Among the 65 studies that remained, an additional 46 articles were excluded for various reasons: 31 were review articles; eleven were discarded because screening of *APC* promoter methylation was performed using cell lines; and four were excluded because of a lack of data on the association between *APC* promoter methylation and the development of CRC. Thus, 19 articles were ultimately selected for inclusion in the meta-analysis.[@b20-ott-8-211]--[@b38-ott-8-211]

Study characteristics
---------------------

The characteristics of the studies that met all of the established inclusion criteria for the meta-analysis are presented in [Table 1](#t1-ott-8-211){ref-type="table"}. Nine eligible studies presented data on the association between *APC* promoter methylation and the risk of developing CRC. Eleven studies assessed the correlation of *APC* promoter methylation with the presence of CRC metastasis. Four studies reported the association between *APC* promoter methylation and the presence of colorectal adenoma. In addition, the numbers of articles that reported the associations between APC promoter methylation and age of the CRC patients, sex of the CRC patients, and CRC differentiation status were 3, 6, and 4, respectively. Of the 19 included studies, ten enrolled Asian participants and nine enrolled Caucasian participants. For the detection of *APC* promoter methylation, 12 studies used methylation-specific polymerase chain reaction, five used quantitative real-time methylation-specific polymerase chain reaction (Q-MSP), and two used the pyrosequencing method. In addition, 17 studies used colorectal tissue specimens to screen for *APC* promoter methylation, while two studies used plasma or serum samples.

Data quality
------------

We estimated the quality of the studies using the NOS evaluation system, and the results showed that 15 of the 19 studies were classified as high-quality (NOS score \>6) and the remaining four trials were classified as lower-quality. The mean NOS score of the studies was 7. Most of the studies did not use community controls when we conducted an assessment of comparability.

Methylation of the *APC* promoter and CRC
-----------------------------------------

As shown in [Figure 2](#f2-ott-8-211){ref-type="fig"}, the pooled outcome of nine studies comprising 740 subjects indicated that *APC* promoter methylation was significantly associated with an increased risk of developing CRC (pooled OR 5.53; 95% CI 3.50--8.76, *P*\<0.01; power 1.0). Eleven studies comprising 1,219 patients evaluated the association between *APC* promoter methylation and CRC metastasis, and the pooled OR was 0.80 at a 5% significance level with 5% power (95% CI 0.44--1.46, *P*=0.47; [Figure 3](#f3-ott-8-211){ref-type="fig"}). Four studies assessed the association between *APC* promoter methylation and the presence of colorectal adenoma, and the pooled OR was 1.85 at a 5% significance level with 94% power (95% CI 0.67--5.10, *P*=0.23; [Figure 4](#f4-ott-8-211){ref-type="fig"}). We also evaluated the association between *APC* promoter methylation and patient age, patient sex, TNM stage, Dukes' stage, and differentiation grade, and no significant association was identified between *APC* promoter methylation and these specific parameters ([Table 2](#t2-ott-8-211){ref-type="table"}).

We conducted subgroup analyses to further explore the potential effects of the adopted screening methods, the ethnicities of the study populations, the testing materials used, and the study sample sizes on the association of *APC* promoter methylation with the risk of CRC ([Table 3](#t3-ott-8-211){ref-type="table"}). When the studies were stratified according to ethnicity, the combined OR was 4.54 (95% CI 1.89--10.92; *P*\<0.01) for studies conducted with Asian populations and 10.03 (95% CI 3.44--29.19; *P*\<0.01) for studies conducted with Caucasian populations. Subgroup analyses of the testing materials used suggested that the exposure rate of *APC* promoter methylation in CRC tissues was higher than that in normal tissues (pooled OR 4.13; 95% CI 2.39--7.15; *P*\<0.01). In addition, a significant correlation between *APC* promoter methylation and the risk of developing CRC was detected in studies that used both methylation-specific polymerase chain reaction (pooled OR 8.04; 95% CI 4.22--15.32; *P*\<0.01) and Q-MSP (pooled OR 3.07; 95% CI 1.52--6.16; *P*\<0.01). Moreover, the overall outcome was not significantly altered by the sample size in the subgroup analysis.

The subgroup analyses, which were stratified according to the methylation screening methods adopted, the ethnicity of the study population, the testing materials used, and the study sample sizes, were conducted to detect potential clinical heterogeneity among the studies that investigated the association between *APC* promoter methylation and CRC metastasis ([Table 4](#t4-ott-8-211){ref-type="table"}). None of these factors significantly affected the overall outcome of the association between *APC* promoter methylation and CRC metastasis.

The sensitivity analyses showed that the pooled ORs were not significantly affected following the sequential exclusion of each study ([Figures S1](#SD1-ott-8-211){ref-type="supplementary-material"}--[S3](#SD3-ott-8-211){ref-type="supplementary-material"}). In addition, pooling the data of the high-quality studies during the sensitivity analyses did not significantly change the overall results of the meta-analysis. The funnel plot ([Figure S4](#SD4-ott-8-211){ref-type="supplementary-material"}) and Egger's test did not reveal significant publication biases in the current meta-analysis (CRC risk, Egger's test, *P*=0.48; CRC metastasis status, Egger's test, *P*=0.85; colorectal adenoma status, Egger's test, *P*=0.85).

Discussion
==========

The main findings of this meta-analysis indicated that *APC* promoter methylation was significantly associated with a higher risk of developing CRC. Additional subgroup analyses of the adopted methylation screening methods, ethnicities of the study populations, the testing materials used, and the sample sizes did not significantly alter the overall results. Both the overall and subgroup analyses regarding the association between *APC* promoter methylation and CRC metastasis suggested that *APC* promoter methylation was not significantly associated with the presence of CRC metastasis. Furthermore, this meta-analysis did not identify a significant association between *APC* promoter methylation and CRC adenoma, patient age, patient sex, TNM stage, Dukes' stage, or differentiation grade.

It is well known that CRC has relatively low 5-year survival rate worldwide.[@b1-ott-8-211] However, CRC is curable in \>90% cases if detected at an early stage.[@b39-ott-8-211] Therefore, the development and improvement of early screening methods are essential to increasing the survival rate and clinical outcomes for patients with CRC. In addition, the excision of precancerous polyps under early screening programs is one of the most effective methods used to decrease the incidence and mortality rate of CRC.[@b3-ott-8-211],[@b40-ott-8-211],[@b41-ott-8-211] It has been suggested that the fecal occult blood test, a commonly used screening method for CRC, can decrease CRC-related mortality by 20% when conducted every 2 years;[@b42-ott-8-211] however, the fecal occult blood test still has a comparatively low detection rate for early-stage CRC and precancerous lesions.[@b43-ott-8-211] Although other screening tests such as colonoscopy, flexible sigmoidoscopy, and virtual colonoscopy are more robust, they are partially limited by their relatively high cost, complex preparation procedures, and low compliance rates in the screening and surveillance of CRC.[@b44-ott-8-211] Therefore, the identification of CRC biomarkers has attracted more attention and may hold great potential as a new screening method for the prevention and subsequent treatment of CRC.[@b7-ott-8-211]

The present meta-analysis indicated that the percentage of *APC* promoter methylation in specimens of CRC was significantly higher than in normal samples, which is consistent with the result of a previous meta-analysis of *APC* promoter methylation and prostate cancer.[@b45-ott-8-211] These findings suggest that *APC* promoter methylation may be a valuable biomarker for CRC carcinogenesis. In addition, that methylated DNA can be detected with a high degree of sensitivity and specificity provides evidence that this methodology may be helpful in disease diagnosis and risk stratification.[@b7-ott-8-211],[@b46-ott-8-211] Thus, testing for *APC* promoter methylation may be useful as a practical method for CRC screening. However, we did not identify a significant association between *APC* promoter methylation and CRC metastasis, Dukes' stage, TNM stage, or differentiation grade, which suggests that this method may be inappropriate for use when predicting the developmental stage of CRC. This needs to be further evaluated by additional high-quality studies.

The evaluation of heterogeneity among studies is an essential requirement when performing a meta-analysis.[@b47-ott-8-211] In this meta-analysis, heterogeneity among the studies was detected using the chi-square-based *Q*-test and the *I*^2^ test. Following a systematic assessment, we found no significant heterogeneity between the studies that had investigated the association between *APC* promoter methylation and the risk of developing CRC. Subgroup analyses were conducted to evaluate the clinical heterogeneity of the included studies that investigated the association between *APC* promoter methylation and the risk of developing CRC or CRC metastasis, and no significant heterogeneity was found. In addition, sensitivity analyses were performed to explore the effects of individual studies and study quality on each overall outcome, and no single sensitive study was found in this meta-analysis. Publication bias has also been considered a major concern for a robust meta-analysis. Thus, we used the funnel plot and Egger's test to estimate the influence of publication bias, and no significant publication bias was identified in our study. The aim of a meta-analysis is to aggregate information in order to achieve higher statistical power in the study. However, problems associated with low statistical power may exist even after combining the included studies in the meta-analysis. Therefore, we performed a test to evaluate the statistical power of the pooled results. The power of the positive results of this meta-analysis ranged from 0.96 to 1.0, indicating that these positive results are credible.[@b48-ott-8-211],[@b49-ott-8-211]

The present meta-analysis has several limitations. First, we could not rule out the effects of potential confounders such as xenoestrogens, folate, and diet on the findings of this meta-analysis due to a lack of information presented for both the case and control groups in the studies that were reviewed. Second, the meta-analysis was based on data from observational studies, which may have some potential recall and selection biases that we could not rule out. Third, although no significant publication bias was found in this investigation, null findings may not have been published in the analyzed studies that had considered *APC* promoter methylation as a secondary outcome. In addition, the power value was lower than 0.8 in part of the overall and subgroup analyses of the meta-analysis with negative results. This indicated that the combined sample size was still too small to yield statistical power, even when we pooled the results of the included studies.[@b48-ott-8-211],[@b49-ott-8-211] Therefore, these results need to be bolstered by additional high-quality studies with larger sample sizes in the future.

Conclusion
==========

In conclusion, *APC* promoter methylation was found to be significantly associated with the risk of developing CRC, which suggested that *APC* promoter methylation may be a promising biomarker for the early screening of CRC. In addition, this meta-analysis did not find a significant association between *APC* promoter methylation and CRC metastasis, colorectal adenoma status, patient age, patient sex, TNM stage, Dukes' stage, or differentiation grade. The conclusions of the current study need to be evaluated further through well-designed prospective studies with larger sample sizes. In addition, findings might be more convincing if the studies can effectively rule out the potential effects of various confounding factors.

Supplementary materials
=======================

###### 

Sensitivity analyses of the association between *APC* promoter methylation and the risk of colorectal cancer.

**Abbreviation:** CI, confidence interval.

###### 

Sensitivity analyses of the association between *APC* promoter methylation in samples of colorectal cancer and samples of colorectal cancer metastasis.

**Abbreviation:** CI, confidence interval.

###### 

Sensitivity analyses of the association between *APC* promoter methylation in samples of colorectal cancer and colorectal adenoma.

**Abbreviation:** CI, confidence interval.

###### 

Funnel plot for the evaluation of the potential publication bias in the association between *APC* promoter methylation in samples of colorectal cancer and samples of colorectal cancer metastasis.

**Abbreviations:** OR, odds ratio; SE, standard error.
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![Meta-analysis of the association between *APC* promoter methylation and the risk of colorectal cancer. The circles and horizontal lines correspond to the study specific OR and 95% CI. The sizes of the data markers indicate the weight of each study in the analysis. The diamond represents the pooled OR and its 95% CI; the result was obtained using a fixed-effect model.\
**Abbreviations:** CI, confidence interval; OR, odds ratio.](ott-8-211Fig2){#f2-ott-8-211}

![Meta-analysis of the association between *APC* promoter methylation in samples of colorectal cancer and samples of colorectal cancer metastasis. The circles and horizontal lines correspond to the study specific OR and 95% CI. The sizes of the data markers indicate the weight of each study in the analysis. The diamond represents the pooled OR and its 95% CI; the result was obtained using a random-effect model.\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** CI, confidence interval; OR, odds ratio.](ott-8-211Fig3){#f3-ott-8-211}

![Meta-analysis of the association between *APC* promoter methylation in samples of colorectal cancer and colorectal adenoma. The circles and horizontal lines correspond to the study specific OR and 95% CI. The sizes of the data markers indicate the weight of each study in the analysis. The diamond represents the pooled OR and its 95% CI; the result was obtained using a random-effect model.\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** CI, confidence interval; OR, odds ratio.](ott-8-211Fig4){#f4-ott-8-211}

###### 

Characteristics of the studies included in the meta-analysis

  Reference                                Year   Country        Race        Methods          Sample   CRC metastasis   Colorectal adenoma   Age   Sex   TNM stages   Dukes' stages   Differentiation grade   Study quality
  ---------------------------------------- ------ -------------- ----------- ---------------- -------- ---------------- -------------------- ----- ----- ------------ --------------- ----------------------- ---------------
  Pack et al[@b20-ott-8-211]               2013   Korea          Asian       MSP              Plasma   N                Y                    N     N     N            N               N                       8
  Kang et al[@b21-ott-8-211]               2012   Korea          Asian       Q-MSP            Tissue   Y                N                    Y     Y     Y            N               N                       8
  Gay et al[@b22-ott-8-211]                2012   UK             Caucasian   Pyrosequencing   Tissue   Y                N                    N     Y     N            Y               Y                       8
  Leong et al[@b23-ott-8-211]              2011   UK             Caucasian   Q-MSP            Tissue   N                N                    N     N     N            N               N                       7
  Naghibalhossaini et al[@b24-ott-8-211]   2011   Iran           Asian       MSP              Tissue   Y                N                    Y     Y     Y            N               Y                       8
  Syed et al[@b25-ott-8-211]               2011   Kashmir        Asian       MSP              Tissue   Y                N                    Y     Y     N            Y               N                       8
  Kim et al[@b26-ott-8-211]                2010   Korea          Asian       Pyrosequencing   Tissue   Y                N                    N     N     Y            N               Y                       6
  Belshaw et al[@b27-ott-8-211]            2010   UK             Caucasian   Q-MSP            Tissue   N                N                    N     N     N            N               N                       7
  Kamiyama et al[@b28-ott-8-211]           2009   Japan          Asian       Q-MSP            Tissue   N                N                    N     N     N            N               N                       8
  Derks et al[@b29-ott-8-211]              2006   European/USA   Caucasian   MSP              Tissue   N                N                    N     N     N            N               N                       5
  Iacopetta et al[@b30-ott-8-211]          2006   Australia      Caucasian   Q-MSP            Tissue   Y                N                    N     Y     N            N               N                       7
  Leung et al[@b31-ott-8-211]              2005   China          Asian       MSP              Serum    Y                N                    N     Y     Y            N               N                       9
  Chen et al[@b32-ott-8-211]               2005   Germany        Caucasian   MSP              Tissue   Y                N                    N     N     N            N               N                       6
  Ebert et al[@b33-ott-8-211]              2005   Germany        Caucasian   MSP              Tissue   Y                N                    N     N     N            N               N                       8
  Kim et al[@b34-ott-8-211]                2005   Korea          Asian       MSP              Tissue   N                Y                    N     N     N            N               N                       7
  Brandes et al[@b35-ott-8-211]            2005   Netherlands    Caucasian   MSP              Tissue   Y                N                    N     N     N            Y               N                       7
  Xu et al[@b36-ott-8-211]                 2004   China          Asian       MSP              Tissue   N                Y                    N     N     N            N               N                       8
  Lee et al[@b37-ott-8-211]                2004   Korea          Asian       MSP              Tissue   N                Y                    N     N     N            N               N                       7
  Lind et al[@b38-ott-8-211]               2004   Norway         Caucasian   MSP              Tissue   Y                N                    N     N     N            Y               Y                       6

**Notes:** Quality of the studies was assessed using the Newcastle-Ottawa quality assessment scale. A score \>6 indicated a higher-quality study, whereas a score ≤6 indicated a lower-quality study; Y indicates that the study was evaluated for the corresponding prognostic factor; N indicates that the study was not evaluated for the corresponding prognostic factor.

**Abbreviations:** CRC, colorectal cancer; MSP, methylation-specific polymerase chain reaction; Q-MSP, quantitative real-time MSP; TNM, tumor-node-metastasis.

###### 

Meta-analysis of the association between *APC* promoter methylation and the clinical characteristics of patients with colorectal cancer

                          Case type/control type   Studies (n)   Cases/controls   OR (95% CI)         Test of heterogeneity   *P*[c](#tfn5-ott-8-211){ref-type="table-fn"}   Power (1 -- β)   
  ----------------------- ------------------------ ------------- ---------------- ------------------- ----------------------- ---------------------------------------------- ---------------- ------
  Age (years)             \>60/\<60                3             150/146          1.11 (0.16--7.55)   0.001                   87.4                                           0.91             0.48
  Sex                     Male/female              6             402/320          1.42 (1.00--2.02)   0.50                    0.001                                          0.051            0.83
  TNM stage               I +/III + IV             4             312/217          1.12 (0.70--1.80)   0.97                    0.001                                          0.64             0.34
  Dukes' stage            A + B/C + D              4             194/163          0.98 (0.20--4.87)   0.001                   90.1                                           0.98             0.14
  Differentiation grade   Poor/moderate or well    4             117/480          0.87 (0.49--1.57)   0.30                    18.2                                           0.66             0.99

**Notes:**

*P* for heterogeneity. The statistical heterogeneity was assessed using Cochran's test. *P*\<0.1 was considered to indicate significant heterogeneity across the studies

*I*^2^ for heterogeneity; the *I*^2^ statistic was also calculated using Cochran's test; *I*^2^\>50% was considered to indicate significant heterogeneity across the studies.

*P* for meta-analysis. *P*\<0.05 was considered to indicate a significant association between *APC* promoter methylation and the risk of colorectal cancer using fixed-effect or random-effect models.

**Abbreviations:** CI, confidence interval; OR, odds ratio; TNM, tumor-node-metastasis.

###### 

Subgroup analyses of *APC* promoter methylation and the risk of colorectal cancer stratified according to the previously defined study characteristics

                       Studies (n)   Cases/controls   OR (95% CI)           Test of heterogeneity   *P*[c](#tfn9-ott-8-211){ref-type="table-fn"}   Power (1 -- β)   
  -------------------- ------------- ---------------- --------------------- ----------------------- ---------------------------------------------- ---------------- ------
  Subgroup analysis                                                                                                                                                 
   Race                                                                                                                                                             
    Asian              5             399/154          4.54 (1.89--10.92)    0.06                    56.3                                           *P*\<0.01        1.0
    Caucasian          4             121/66           10.03 (3.44--29.19)   0.20                    27.3                                           *P*\<0.01        0.99
   Testing materials                                                                                                                                                
    Tissue             8             460/160          4.13 (2.39--7.15)     0.30                    17.0                                           *P*\<0.01        1.0
    Plasma             1             60/60            9.90 (3.87--25.32)    --                      --                                             *P*\<0.01        1.0
   Testing methods                                                                                                                                                  
    MSP                5             313/128          8.04 (4.22--15.32)    0.75                    0.001                                          *P*\<0.01        1.0
    Q-MSP              4             207/92           3.07 (1.52--6.16)     0.17                    40.2                                           *P*\<0.01        1.0
   Sample size                                                                                                                                                      
    \<100              5             160/71           7.44 (2.75--20.11)    0.74                    0.001                                          *P*\<0.01        1.0
    ≥100               4             360/149          4.86 (2.90--8.17)     0.04                    63.9                                           *P*\<0.01        0.96

**Notes:**

*P* for heterogeneity. The statistical heterogeneity was assessed using Cochran's test. *P*\<0.1 was considered to indicate significant heterogeneity across the studies.

*I*^2^ for heterogeneity. The *I*^2^ statistic was also calculated using Cochran's test. *I*^2^\>50% was considered to indicate significant heterogeneity across the studies.

*P* for meta-analysis. *P*\<0.05 was considered to indicate significant association between *APC* promoter methylation and the risk of colorectal cancer using fixed-effect or random-effect models.

**Abbreviations:** CI, confidence interval; OR, odds ratio; MSP, methylation-specific polymerase chain reaction; Q-MSP, quantitative real-time MSP.

###### 

Subgroup analyses of *APC* promoter methylation and colorectal metastasis stratified according to previously defined study characteristics

                       Studies (n)   Cases/controls   OR (95% CI)         Test of heterogeneity   *P*[c](#tfn13-ott-8-211){ref-type="table-fn"}   Power (1 -- β)   
  -------------------- ------------- ---------------- ------------------- ----------------------- ----------------------------------------------- ---------------- ------
  Subgroup analysis                                                                                                                                                
   Race                                                                                                                                                            
    Asian              5             350/265          0.58 (0.19--1.79)   0.001                   81.1                                            *P*=0.34         0.08
    Caucasian          6             344/260          1.04 (0.52--2.09)   0.02                    63.7                                            *P*=0.91         0.03
   Testing materials                                                                                                                                               
    Tissue             10            674/500          0.81 (0.44--1.51)   0.001                   75.4                                            *P*=0.52         0.09
    Plasma             1             20/25            0.61 (0.05--7.20)   --                      --                                              *P*=0.69         0.04
   Testing methods                                                                                                                                                 
    MSP                7             256/223          0.67 (0.18--2.03)   0.001                   72.8                                            *P*=0.42         0.03
    Q-MSP              2             182/117          0.94 (0.58--1.55)   0.49                    0.001                                           *P*=0.81         0.08
    Pyrosequencing     2             256/185          1.23 (0.75--2.02)   0.79                    0.001                                           *P*=0.42         0.01
   Sample size                                                                                                                                                     
    \<100              7             256/223          0.61 (0.18--2.03)   0.001                   81.1                                            *P*=0.42         0.04
    ≥100               4             438/302          1.08 (0.76--1.53)   0.78                    0.001                                           *P*=0.68         0.03

**Notes:**

*P* for heterogeneity. The statistical heterogeneity was assessed using Cochran's test. *P*\<0.1 was considered to indicate significant heterogeneity across the studies.

*I*^2^ for heterogeneity. The *I*^2^ statistic was also calculated using Cochran's test. *I*^2^\>50% was considered to indicate significant heterogeneity across the studies.

*P* for meta-analysis. *P*\<0.05 was considered to indicate significant association between *APC* promoter methylation and the risk of colorectal metastasis using fixed-effects or random-effects models.

**Abbreviations:** CI, confidence interval; OR, odds ratio; MSP, methylation-specific polymerase chain reaction; Q-MSP, quantitative real-time MSP.
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